Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» EMA committee backs conditional approval of Merck & Co., Endocyte's Vynfinit for ovarian cancer
EMA committee backs conditional approval of Merck & Co., Endocyte's Vynfinit for ovarian cancer
EMA committee backs conditional approval of Merck & Co., Endocyte's Vynfinit for ovarian cancer
Submitted by
admin
on March 21, 2014 - 8:50am
Source:
First Word Pharma
News Tags:
Europe
Merck
Endocyte
Vynfinit
ovarian cancer
Headline:
EMA committee backs conditional approval of Merck & Co., Endocyte's Vynfinit for ovarian cancer
Do Not Allow Advertisers to Use My Personal information
